|
1 Executive Summary
2 Introduction to OTC Pharmaceuticals
2.1 Over-the-Counter or Behind-the-Counter: What are OTC Pharmaceuticals?
2.2 Key Features of OTC Pharmaceuticals
2.3OTC Switching
2.4 Manufacture and Distribution of OTC Pharmaceuticals
2.5 Regulation of OTC Pharmaceuticals
2.5.1 United States
2.5.2 Japan
2.5.3 European Union
2.5.4 Other Countries
2.6 Major Therapeutic Areas for OTC Pharmaceuticals
2.6.1 Analgesics
2.6.1.1 Internal Analgesics
2.6.1.2 External Analgesics
2.6.2 Cough, Cold, and Allergy Products
2.6.3 Gastrointestinal Products
2.6.4 Medicated Skincare Products
2.6.4.1 Minor Cuts and Wounds
2.6.4.2 Acne
2.6.4.3 Rashes, Itchy Skin, Dermatitis and Eczema
2.6.4.4 Cold Sores
2.6.4.5 Warts
2.6.4.6 Fungal Skin Infections
2.6.4.7 Haemorrhoids
2.6.4.8 Other Medicated Skincare Products
2.6.5 Vitamins, Minerals & Supplements
2.6.6 Other OTC Pharmaceuticals
3 The Global OTC Pharmaceutical Market
3.1 The World Market for OTC Pharmaceuticals Will Almost Double in Size by 2023
3.2 Which are the Largest OTC Therapeutic Categories?
3.3 The Leading Global OTC Pharmaceutical Manufacturers
3.3.1 Johnson & Johnson
3.3.2 Bayer
3.3.3 GSK
3.3.4 Novartis
3.3.5 Wyeth
3.4 The Leading World OTC Brands
3.4.1 Tylenol is the Only Global Billion Dollar OTC Brand
3.4.2 Claritin Will Loose Its Dominant OTC Market Position
3.4.3 Prilosec OTC Will Face Competition from Generics and New OTC Switches
3.5 The OTC Market is Rapidly Changing
4 SWOT Analysis of the OTC Pharmaceutical Industry
4.1 SWOT Chart
4.2 OTC Switching
4.3 Changing World Demographics
4.4 Developments in Wholesale and Retail Channels
4.5 Brand Identity and Private Labels
4.6 Will OTC Move Behind-the-Counter?
4.7 New Advertising Opportunities
4.8 Safety Concerns Over Misuse and Abuse of OTC Pharmaceuticals
5 The OTC Pharmaceutical Market by Geographical Area
5.1 The World OTC Market: China and India Will Increase Their Market Share
5.2 The US OTC Market
5.2.1 The US OTC market in 2007
5.2.2 The US OTC Market 2008-2013
5.3 The Japanese OTC Market
5.3.1 The Japanese OTC Market in 2007
5.3.2 Leading Japanese OTC Pharmaceutical Companies
5.3.2.1 Taisho
5.3.2.2 Takeda
5.3.2.3 Daiichi Sankyo
5.3.2.4 Lion
5.3.3 The Japanese OTC Market 2008-2013
5.4 The European OTC Market
5.4.1 The European OTC Market in 2007
5.4.2 The European OTC market 2008-2013
6 Prescription-Only to OTC Switching
6.1 Recent Switching Activity
6.2 Gastrointestinal OTC Switching
6.3 Cough, Cold and Allergy OTC Switching
6.4 Analgesic OTC Switching
6.5 Medicated Skincare OTC Switching
6.6 Cholesterol-Lowering OTC Switching
6.7 Erectile Dysfunction OTC Switching
6.8 OTC Switching: A Continuing Trend in 2008-2023
7 Conclusions
List of Tables
Table 3.1 World Sales Forecast ($bn) for OTC Pharmaceuticals 2006-2023
Table 3.2 World Sales ($bn) for OTC Pharmaceuticals by Therapeutic Class 2007
Table 3.3 World OTC Sales Forecast ($bn) by Therapeutic Category 2006-2023
Table 3.4 Sales ($bn) of Top Five World OTC Manufacturing Companies 2007
Table 3.5 Tylenol Worldwide Sales Forecast ($bn) 2007-2023
Table 3.6 Claritin (OTC) Worldwide Sales Forecast ($bn) 2007-2023
Table 3.7 Prilosec OTC Worldwide Sales Forecast ($bn) 2007-2023
Table 4.1 SWOT Chart for the OTC Pharmaceutical Industry
Table 4.2 World Population 2007-2023
Table 4.3 China, India, US & Japan Population 2007-2023
Table 4.4 GDP ($tr) US, Japan, China & India 2007-2023
Table 5.1 OTC Pharmaceutical Sales by Country 2007
Table 5.2 OTC Share of Pharma Market by Country 2007
Table 5.3 Forecast World Sales ($bn) of OTC Pharmaceuticals by Country 2007-2023
Table 5.4 OTC Therapeutic Areas US 2007
Table 5.5 Largest selling OTC Pharmaceutical Brands in the US 2007
Table 5.6 Sales ($m) of alli in the US 2007-2013
Table 5.7 OTC Therapeutic Areas in Japan 2006
Table 5.8 Leading Japanese OTC Manufacturing Companies 2006-07
Table 5.9 Leading Cough, Cold and Allergy Brands in Japan 2008-2013
Table 5.10 Sample European OTC Country Markets 2007
Table 5.11 OTC Therapeutic Areas in Europe 2007
Table 6.1 Selected Recent Prescription-Only to OTC Switches
Table 6.2 Selected Possible Future OTC Switches
Table 7.1 Leading OTC Country Markets 2007 & 2023
List of Figures
Figure 1.1 World Sales Forecast ($bn) for OTC Pharmaceuticals 2007-2023
Figure 2.1 The OTC Pharmaceutical Supply Chain
Figure 3.1 World Sales Forecast ($bn) for OTC Pharmaceuticals 2007-2023
Figure 3.2 World Sales Forecast ($bn) for Pharmaceuticals 2007-2023
Figure 3.3 World OTC Sales Forecast ($bn) by Therapeutic Category 2007-2023
Figure 3.4 Share of World OTC Pharmaceutical Sales by Therapeutic Category 2007
Figure 3.5 Forecast Share of World OTC Sales by Therapeutic Category 2013
Figure 3.6 Forecast Share of World OTC Sales by Therapeutic Category 2018
Figure 3.7 Forecast Share of World OTC Sales by Therapeutic Category 2023
Figure 3.8 Sales ($bn) of Top Five World OTC Manufacturing Companies 2007
Figure 3.9 Tylenol, Prilosec OTC and Claritin (OTC) World Sales Forecast 2007-2023
Figure 4.1 Populations of US, Japan, China and India 2007-2023
Figure 4.2 Population Aged 65 or Over in US, Japan, China and India 2007-2023
Figure 4.3 Populations % Aged 65 or Over in US, Japan, China and India 2007-2023
Figure 4.4 Gross Domestic Product ($tr) for US, Japan, China and India 2007-2023
Figure 5.1 Forecast Sales ($bn) of OTC Pharmaceuticals by Country 2007-2023
Figure 5.2 Forecast Sales ($bn) of OTC Pharmaceutical by Country 2007-2023
Figure 5.3 Market Share of World OTC Pharmaceutical Sales by Country 2007
Figure 5.4 Forecast Market Share of World OTC Pharmaceuticals Sales by Country 2013
Figure 5.5 Forecast Market Share of World OTC Pharmaceuticals Sales by Country 2018
Figure 5.6 Forecast Market Share of World OTC Pharmaceuticals Sales by Country 2023
Figure 5.7 Sales ($m) of alli in the US 2007-2013
Figure 5.8 Leading Japanese OTC Pharmaceutical Companies 2006-07
Figure 5.9 Leading Cough, Cold and Allergy Brands in Japan 2008-2013
|